NCT00598910

Effect of Omacor on Triglycerides in HIV Infected Subjects

A Double-Blind, Placebo-Controlled, Parallel-Group, Multi-Center Study to Investigate the Effect of Omacor (n-3 PUFA) on Lipid Parameters in HIV Infected Subjects Treated With HAART

• Status: Terminated
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 51 (actual)
• Sponsor: Solvay Pharmaceuticals · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

Omacor is likely to decrease lipid parameters in HIV infected subjects. In these subjects the lipid are decrease due to HAART treatment

Conditions

• Hyper-Triglyceridemia

Interventions

Type	Name	Description
DRUG	Omacor	n-3 PUFA
DRUG	Placebo	Placebo

Timeline

• Start date: 2007-08-01
• Primary completion: 2008-09-01
• Completion: 2009-03-01
• First posted: 2008-01-23
• Last updated: 2009-03-30

Locations

5 sites across 2 countries: Germany, United Kingdom